Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to a loss of $0.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.01%. A quarter ago, it was expected that this company would post a loss of $1.27 per share when it actually produced a loss of $1.38, delivering a surprise of -8.66%.Over the last four quarters, the co ...

Group 1: Market Movements - Biotech and healthcare companies experienced notable movements in after-hours trading, with several small-cap firms showing strong gains due to corporate updates and investor momentum [1] Group 2: Company Updates - Plus Therapeutics, Inc. (PSTV) surged 8.40% to close at $0.31 after announcing a public offering priced at $0.38 per unit, aiming to raise approximately $15 million to support its precision diagnostics and radiopharmaceutical programs targeting central nervous system cancers [2] - Connect Biopharma Holdings Limited (CNTB) gained 5.96% to $2.31, recently highlighting new mechanism of action data for its lead candidate and outlining strategic priorities for 2026 [3] - ABVC BioPharma, Inc. (ABVC) added 3.37% to finish at $2.15, with the increase attributed to broader sector momentum rather than new corporate updates [3] - Modular Medical, Inc. (MODD) advanced 5.23% to $0.49, experiencing renewed buying interest despite no new news [4] - Traws Pharma, Inc. (TRAW) rose 2.82% to $1.82 after announcing the filing of a U.S. IND application for its potential oral therapy for influenza, supporting investor optimism around its pipeline [4] - Tiziana Life Sciences Ltd (TLSA) posted a 2.72% gain to $1.51 with no new developments reported [5] - Elutia Inc. (ELUT) climbed 6.64% to $0.90, following a corporate update outlining upcoming milestones for its next-generation antibiotic-eluting biomatrix program [5]

Market Overview - U.S. stocks experienced a decline, with the Nasdaq Composite falling over 350 points, the Dow down 0.55% to 48,922.97, the NASDAQ down 1.58% to 23,335.70, and the S&P 500 down 1.06% to 6,889.76 [1] - Energy shares increased by 2%, while information technology stocks decreased by 1.3% [1] Retail Sales and Economic Indicators - U.S. retail sales rose by 0.6% month-over-month in November, marking the largest increase since July, compared to a revised 0.1% drop in October [2][10] - The U.S. current account deficit decreased by 9.2% to $226.4 billion in Q3, against market expectations of a $238 billion gap [10] - U.S. producer prices increased by 0.2% month-over-month in November, consistent with market expectations [10] Commodity Market - Oil prices rose by 1.3% to $61.97, gold increased by 0.5% to $4,622.10, silver surged by 4.8% to $90.560, and copper rose by 0.3% to $6.0345 [5] European and Asian Markets - European shares were mostly higher, with the eurozone's STOXX 600 up 0.19%, Spain's IBEX 35 up 0.43%, London's FTSE 100 up 0.28%, Germany's DAX down 0.40%, and France's CAC 40 up 0.10% [6] - Asian markets closed mixed, with Japan's Nikkei up 1.48%, Hong Kong's Hang Seng Index up 0.56%, China's Shanghai Composite down 0.31%, and India's BSE Sensex down 0.29% [7] Company-Specific Movements - High Roller Technologies, Inc. shares surged by 289% to $13.64 after announcing a partnership with Crypto.com [9] - Clover Health Investments Corp shares rose by 10% to $2.78 following a year-over-year increase in membership growth [9] - Inspire Veterinary Partners Inc shares increased by 78% to $0.041 after filing to increase its authorized common stock [9] - Briacell Therapeutics Corp shares fell by 53% to $5.09 after pricing a public offering at $5.59 per unit [9] - Plus Therapeutics Inc shares dropped by 39% to $0.29 after announcing a public offering priced at $0.38 per unit [9] - Hub Cyber Security Ltd shares decreased by 39% to $0.33 following a reverse stock split announcement [9]

Market Overview - U.S. stocks traded lower, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow decreased by 0.21% to 49,090.31, the NASDAQ declined by 0.67% to 23,551.77, and the S&P 500 fell by 0.47% to 6,931.31 [1] Company Earnings - Bank of America Corp reported a net income of $7.6 billion for Q4 fiscal 2025, down from $6.80 billion a year ago. The EPS was 98 cents, beating the analyst consensus estimate of 96 cents. Revenue increased by 7% year-over-year to $28.532 billion, surpassing the analyst consensus estimate of $27.944 billion [2] Commodity Prices - Oil prices increased by 1% to $61.73, gold rose by 1% to $4,643.70, silver surged by 5.8% to $91.365, and copper gained 0.5% to $6.0450 [5] Stock Movements - High Roller Technologies, Inc. shares surged by 322% to $14.65 after announcing a partnership with Crypto.com. Lottery.com Inc shares increased by 87% to $0.96, while Inspire Veterinary Partners Inc shares rose by 99% to $0.046 following an increase in authorized common stock. Conversely, Briacell Therapeutics Corp shares dropped by 53% to $5.11 after pricing a public offering at $5.59 per unit. Plus Therapeutics Inc shares fell by 41% to $0.28 after announcing a public offering at $0.38 per unit. Hub Cyber Security Ltd shares decreased by 40% to $0.32 after a reverse stock split announcement [8]

Group 1: Company Performance - Gelteq Ltd (NASDAQ:GELS) shares rose sharply by 50.1% to $1.25 in pre-market trading after reporting positive preclinical results for its cannabinoid oral gel delivery platform [1][2] - The proprietary oral gel platform achieved a greater than 22% increase in the bioavailability of cannabidiol compared to an existing FDA-approved oil-based product [1] Group 2: Other Notable Stock Movements - Inspire Veterinary Partners Inc (NASDAQ:IVP) gained 141.3% to $0.056 after filing a Certificate of Amendment to increase its authorized Class A common stock from 100 million to 700 million shares [5] - Oriental Culture Holding Ltd (NASDAQ:OCG) rose 40.8% to $0.016 following the board's approval of a special cash dividend of 5 cents per share [5] - XCF Global Inc (NASDAQ:SAFX) gained 30.2% to $0.22 after announcing expansion financing plans [5] - AiRWA Inc (NASDAQ:YYAI) rose 15.8% to $1.46 after a director purchased 1.109 million shares at an average price of $1.35 per share [5] - Autolus Therapeutics PLC (NASDAQ:AUTL) gained 7.3% to $1.47 after announcing preliminary fourth-quarter and FY25 revenue results [5] Group 3: Declining Stocks - Briacell Therapeutics Corp (NASDAQ:BCTX) fell 53.1% to $5.12 after announcing the pricing of a $30 million public offering [5] - Moolec Science SA (NASDAQ:MLEC) fell 19.8% to $3.94 after a previous jump of 19% [5] - Hub Cyber Security Ltd (NASDAQ:HUBC) fell 19.1% to $0.43 after gaining 56% on the previous day [5] - Trip.com Group Ltd (NASDAQ:TCOM) dipped 9.3% to $68.55 amid an investigation by China's SAMR for potential anti-monopoly violations [5]

Core Viewpoint - Bark Inc's shares experienced a significant increase of 19.9% to $0.74 in pre-market trading following a non-binding acquisition proposal from Great Dane, as disclosed in a 13D filing [1] Gainers - Signing Day Sports Inc saw a substantial gain of 43.7% to $0.71 in pre-market trading [4] - Ping An Biomedical Co Ltd rose by 34.3% to $0.27 after a previous decline of 68% on Friday [4] - Abivax SA increased by 23.6% to $141.35, with Morgan Stanley analyst Judah Frommer maintaining an Overweight rating and raising the price target from $101 to $145 [4] - Cellectar Biosciences Inc gained 18.4% to $3.65 after a 7% drop on Friday [4] - China SXT Pharmaceuticals Inc surged 17.5% to $0.18 following an 88% decline on Friday, announcing a $10 million registered direct offering [4] - Kingsoft Cloud Holdings Ltd increased by 13.8% to $12.55 [4] - Critical Metals Corp rose 12.3% to $16.82 after an 11% increase on Friday [4] - Rich Sparkle Holdings Ltd gained 11.7% to $97.00, following a 259% jump on Friday after announcing a $39 million offering of 3 million shares at $13 per share [4] - 3 E Network Technology Group Ltd rose 10.3% to $0.41 after announcing the closing of a $2 million convertible promissory note offering [4] Losers - Lexaria Bioscience Corp fell 12.9% to $0.65 after a 7% gain on Friday [4] - Plus Therapeutics Inc declined 11.8% to $0.49, announcing an offering of 22,321,429 pre-funded units at $0.56 per unit [4] - RenovoRx Inc fell 11.3% to $0.99 after a 3% decline on Friday [4] - Synchrony Financial dipped 9.5% to $78.61 [4] - Eastern International Ltd shares decreased by 9.1% to $1.41 after a 30% increase on Friday [4] - Stoke Therapeutics Inc declined 8.7% to $30.00, announcing updates to timelines for the completion of enrollment and Phase 3 data readout from the EMPEROR study [4] - Capital One Financial Corp fell 8.4% to $228.35 [4] - Bread Financial Holdings Inc tumbled 8.3% to $73.72 [4] - OSR Holdings Inc decreased by 8% to $0.61 after a 6% gain on Friday [4] - Himalaya Shipping Ltd dipped 5.7% to $8.72 [4]

Group 1 - Sify Technologies Ltd. is expected to report a quarterly loss of 1 cent per share on revenue of $165 million, with shares falling 3.3% to $14.50 in after-hours trading [1] - Boot Barn Holdings Inc. reported preliminary third-quarter net sales of $705.6 million, reflecting a growth of 16% year-over-year, while shares slipped 0.4% to $194.95 in after-hours trading [1] - Wealthfront Corp is anticipated to post quarterly earnings of 10 cents per share on revenue of $93.23 million, with shares rising 1.7% to $13.05 in after-hours trading [1] - Plus Therapeutics Inc. announced an offering of 22,321,429 pre-funded units at $0.56 per unit, leading to a 10% dip in shares to $0.50 in after-hours trading [1] - Solowin Holdings Ltd. reported a first-half loss of 7 cents per share, an improvement from a loss of 39 cents per share a year ago, with sales increasing to $5.842 million from $1.055 million, and shares gaining 2.4% to $4.28 in after-hours trading [1]

Core Insights - United Therapeutics reported quarterly earnings of $7.16 per share, exceeding the Zacks Consensus Estimate of $6.89 per share, and up from $6.39 per share a year ago, representing an earnings surprise of +3.92% [1] - The company posted revenues of $799.5 million for the quarter ended September 2025, which was below the Zacks Consensus Estimate by 2.24%, but an increase from $748.9 million year-over-year [2] - United Therapeutics shares have increased approximately 17.7% year-to-date, slightly outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The future performance of United Therapeutics' stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $6.57, with projected revenues of $792.76 million, and for the current fiscal year, the EPS estimate is $26.67 on revenues of $3.2 billion [7] Industry Context - The Medical - Drugs industry, to which United Therapeutics belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The correlation between near-term stock movements and earnings estimate revisions suggests that tracking these revisions can provide insights into stock performance [5]

Core Viewpoint - The drug and biotech sector is experiencing a recovery driven by a landmark drug-pricing deal between Pfizer and the Trump administration, which includes tariff exemptions and price cuts, alongside increased M&A activity in the sector [1]. Group 1: Industry Overview - The Zacks Medical-Drugs industry consists of small to medium-sized drug companies that primarily focus on developing medicines, often relying on collaborations with larger firms for revenue [3]. - The industry is currently ranked 68 in the Zacks Industry Rank, placing it in the top 28% of 243 Zacks industries, indicating strong prospects for growth [9]. Group 2: Market Performance - The Zacks Medical-Drugs industry has seen a year-to-date stock increase of 6.2%, outperforming the Zacks Medical sector, which decreased by 0.2%, but underperforming the S&P 500, which rose by 12.2% [11]. - The industry is trading at a trailing 12-month price-to-sales ratio of 2.37, lower than the S&P 500's 5.82 and the Zacks Medical sector's 2.45 [13]. Group 3: Key Trends and Innovations - There is a strong focus on innovation in areas such as rare diseases, next-generation oncology treatments, obesity, immunology, and neuroscience, which are attracting investor interest [5]. - Investment in technology and personalized medicine is crucial for smaller companies to adapt to the evolving healthcare landscape [7]. Group 4: Company Highlights - **Ironwood Pharmaceuticals**: The company is advancing its key pipeline candidate, apraglutide, for treating short bowel syndrome, with a stock increase of 115.5% in the past three months [16][17]. - **Pyxis Oncology**: The company is progressing with its lead candidate, micvotabart pelidotin, for treating head and neck cancer, with a stock increase of 197.4% in the past three months [20][21]. - **Plus Therapeutics**: Focused on targeted radiotherapeutics for CNS cancers, the company has seen its stock rise by 113.6% in the past three months [24][26]. - **Cardiol Therapeutics**: Developing CardiolRx for heart disease, the company has experienced an 18.6% decline in stock over the past three months [29][31]. - **Akebia Therapeutics**: The company launched Vafseo for anemia due to chronic kidney disease, but its stock has declined by 28.3% in the past three months [33][34].

Core Insights - Merus NV's shares increased by 38.2% to $95.21 following Genmab's announcement of an $8 billion all-cash acquisition deal, which includes the addition of the breakthrough therapy Petosemtamab to Genmab's late-stage pipeline [1] Gainers - Steakholder Foods Ltd rose 92% to $8.32 after announcing an agreement to acquire Twine Solutions [4] - JFB Construction Holdings surged 77.4% to $12.15 following a $44 million private placement announcement [4] - Plus Therapeutics gained 24.3% to $0.77 after securing a national coverage agreement with UnitedHealthcare for its CNSide assay [4] - Avalo Therapeutics rose 24.1% to $13.40 after a previous decline of 6% [4] - Enanta Pharmaceuticals gained 22.7% to $9.69 ahead of presenting topline results from its Phase 2b study of Zelicapavir for RSV [4] - Canopy Growth Corp jumped 19.4% to $1.60 [4] - Zura Bio Ltd gained 18.3% to $2.85 after a 15% increase on Friday [4] - Tilray Brands surged 17.4% to $1.35, with first-quarter financial results to be announced on October 9 [4] - Larimar Therapeutics jumped 16.4% to $5.93, with an update on the Nomlabofusp program scheduled for September 2 [4] Losers - MoonLake Immunotherapeutics dipped 86.3% to $8.50 despite achieving statistically significant results in its Phase 3 VELA trials [4] - Maris Tech fell 37.3% to $2.62 after reporting a H1 loss of 30 cents per share [4] - Sunrise New Energy Co Ltd shares dipped 28.1% to $0.88 after a previous 10% gain [4] - Cycurion Inc declined 15.5% to $0.28 after a significant drop of over 30% on Friday [4] - bioAffinity Technologies dipped 14.4% to $4.53 after a 55% increase on Friday [4] - Youxin Technology Ltd fell 13.9% to $0.058 following a 1-for-80 reverse split announcement [4] - Top KingWin Ltd declined 12.8% to $4.07 after a previous 48% increase [4] - Cellectis SA fell 10.4% to $3.01 [4] - Quantum-Si Inc decreased 10.1% to $1.34 after filing for a mixed shelf of up to $300 million [4] - Penguin Solutions Inc fell 8.4% to $24.00 [4]